Mitofusin 2 gene mutation causing early-onset CMT2A with different progressive courses.

Area of Science:

• Genetics
• Neurology
• Mitochondrial Biology

Background:

• Charcot-Marie-Tooth disease Type 2A2 (CMT2A2) is a genetic peripheral neuropathy linked to mutations in the mitofusin 2 (MFN2) gene.
• Clinical presentations of CMT2A2 are typically categorized into severe early-onset and mild benign forms.

Observation:

• This study reports on three early-onset CMT2A2 patients from China exhibiting distinct disease progression.
• The patients carried mutations R94W, R364W, and a novel W740R in the MFN2 gene.
• Two patients developed progressive distal limb muscle weakness starting at ages 5 and 6, losing ambulation after 35 years; the third patient experienced similar symptoms from birth, never achieving independent walking.

Findings:

• Sural nerve biopsies showed severe axonal neuropathy with mitochondrial aggregation within axons.
• The findings confirm that early-onset CMT2A2 exhibits variable clinical courses in the Chinese population.
• A novel mutation (W740R) in the MFN2 gene was identified, broadening the genotypic spectrum of MFN2-related CMT.

Implications:

• This research highlights the phenotypic heterogeneity of CMT2A2, even within specific ethnic groups.
• The identification of a new MFN2 mutation contributes to a deeper understanding of the genetic basis of CMT.
• Further research into MFN2 mutations can aid in developing targeted diagnostics and therapies for CMT2A2.